Zealand Pharma's stock experienced a sharp decline, plunging more than 35% after the company released mid-stage trial results for its experimental weight-loss drug, petrelintide, which fell short of market expectations [1]. The trial showed an average weight reduction of 10.7% over 42 weeks, whereas analysts had anticipated a range between 13% and 20% [1]. This disappointing outcome triggered Zealand's worst trading day ever, with shares reaching their lowest level since August 2023. Roche, Zealand's partner in developing petrelintide, also saw its shares drop by 3% [1].
CEO Adam Steensberg addressed the market reaction in an interview with CNBC, emphasizing that the trial was not optimized for maximum weight loss and highlighting the drug's potential for weight maintenance and tolerability, with very few side effects [1]. Steensberg criticized the industry's focus on what he termed the 'weight loss Olympics,' arguing that the real-world needs of patients are not aligned with the pursuit of the highest possible weight loss numbers. He stated, "The world doesn't need these products that amount to very high rates of weight loss," referencing competitors such as Novo Nordisk and Eli Lilly [1].
Steensberg expressed confidence in a forthcoming industry shift towards prioritizing tolerability and long-term patient adherence over headline weight loss figures. He noted that most patients using current products do not achieve the weight loss numbers seen in clinical studies due to issues with tolerability in real-world settings [1]. The company is positioning itself to differentiate in the lucrative weight-loss drug market, which is estimated to be worth as much as $150 billion by 2030, by focusing on weight maintenance and side effect management [1].
No forward-looking analyst opinions were provided in the article, but Steensberg's comments suggest Zealand will continue to advocate for a broader perspective on weight-loss drug efficacy and patient experience [1].
CONCLUSION
Zealand Pharma's disappointing trial results for petrelintide led to a steep 35% drop in its share price, with Roche also affected. The company is attempting to shift the industry narrative towards weight maintenance and tolerability, but the market reacted strongly to the lower-than-expected weight loss figures. The event underscores the intense scrutiny and high expectations in the competitive weight-loss drug sector.